Innate Pharma S.A. IPHYF
2.25 USD +0.74 +49.11%
At close · Oct 30
- Open
- 2.18
- Prev close
- 1.51
- Mkt cap
- 251.33M
- Vol
- 200
- Avg vol
- 15
- EPS
- -0.59
- P/E
- 0.00
More statistics
- Low
- 2.18
- High
- 2.25
- Earnings
- Mar 21, 2024
3M chart
Chart tools
2026-08-13 O 1.65 H 1.65 L 1.65 C 1.65 V –
Altman Z-Score
-21.86 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
P/E -3.3×
P/S 58.7×
P/B -7.5×
P/FCF -3.1×
EV/EBITDA -3.3×
EV/Sales 56.7×
FCF Yield -32.3%
Gross Margin 100.0%
Operating Margin -1917.7%
Net Margin -1764.5%
ROE 226.6%
ROIC -133.9%
ROA -78.4%
Revenue -77.9%
Operating Income -3.6%
EPS (diluted) 9.8%
Free Cash Flow -625.6%
Current Ratio 1.3×
Quick Ratio 1.3×
Debt / Equity -1.0×
Net Debt / EBITDA 0.1×
Interest Coverage -17.1×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31